Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New principle in cancer treatment found

20.03.2014

Scientists of the Cluster of Excellence CECAD, University of Cologne, have developed a new strategy for cancer treatment.

Tumor growth is dependent on attracting blood vessels, that supply nutrients and oxygen and dispose of metabolic waste. An insufficient blood supply results in significantly reduced tumor growth.

The poisoning of the mitochondria, the cell´s power-plants, inhibits blood vessel growth, but has no effects on existing vessels. For this purpose the scientists used the weak mitochondrial poison Embelin. Selective inhibition of mitochondrial function could represent a fundamentally new therapeutic approach that may help advance the development of cancer treatments.

Cologne, 2014, March 20. A team of researchers from five CECAD departments led by PD Dr. Hamid Kashkar (University Hospital of Cologne, Institute of Clinical Microbiology, Immunology and Hygiene) and Dr. Oliver Coutelle (University Hospital of Cologne, Department of Internal Medicine I) have found a new principle for the treatment of proliferating solid tumors.

Tumors are highly dependent on the growth of blood vessels supplying nutrients and oxygen and excreting CO2 and metabolic waste products. Accordingly, the inhibition of tumor blood vessels by blocking specific vascular growth factors is a strategy that is already being used successfully to treat tumors today.

In close collaboration with Dr. Hue-Tran Hornig-Do and Prof. Dr. Rudolf Wiesner (University Hospital of Cologne, Institut of Vegetative Physiology), the CECCAD team reports in a recent article in EMBO Mol Med, that Embelin, a substance that is used in African traditional medicine, inhibits vessel growth by a novel mechanism.

They showed that Embelin acts as a weak poison for mitochondria, the power plants of cells. They demonstrated that growing blood vessels – but not resting normal blood vessels – are highly dependent on mitochondrial function and have little capacity to compensate for mitochondrial dysfunction induced by Embelin. Together their findings show that Embelin significantly slowed the growth of tumors by inhibiting their blood supply, but had little effect on existing normal blood vessels and other tissues at the concentrations required.

The study was supported by further research in collaboration with Prof. Sabine Eming (University of Cologne, Dermatology). Wound healing experiments demonstrated delayed closure of wounds in the presence of Embelin due to the lack of blood vessel in-growth, providing additional evidence for the effectiveness of Embelin in inhibiting new blood vessel formation.

Experiments in cooperation with Prof. Aleksandra Trifunovic ( CECAD) provide additional support for the dependence of new blood vessels on adequate mitochondrial function. In particular, mitochondrial dysfunction induced by mutation in mitochondrial DNA severely impaired the capacity for vascularisation of implanted artificial plugs, designed to attract new blood vessels.

In summary, the scientists were able to prove that impairment of mitochondrial function provides a fundamentally new approach to inhibit blood vessel growth in solid tumors with little side effects on normal body functions. Prof. Dr. Rudolf Wiesner: „We all feel excited about this new principle that will provide new approaches in the fight against cancer.“

Contact:
Dr. Oliver Coutelle
Email: oliver.coutelle@uk-koeln.de
or
PD Dr. Hamid Kashkar
Email: h.kashkar@uni-koeln.de

Astrid Bergmeister
Leiterin CECAD PR & Marketing
Tel. + 49 (0) 221-478-84043
Email: astrid.bergmeister@uk-koeln.de

Weitere Informationen:

http://www.cecad.uni-koeln.de

Astrid Bergmeister | idw - Informationsdienst Wissenschaft

Further reports about: CECAD blood metabolic mitochondrial nutrients poison tumors vessel

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>